Marjorie Wongskhaluang, MD
Infectious Disease · Leawood, KSNPI 1578797049
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Paratek Pharmaceuticals, Inc. accounts for 78.5% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2020 at $3,575 and has fallen 88.7% since, to $405 in 2025. Among infectious disease clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 57 payments — averaging $81.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Paratek Pharmaceuticals, Inc.$4K
- Melinta Therapeutics, LLC$184
- Insmed, Inc.$171
- Next Science LLC$160
- AbbVie$157
- Viiv Healthcare Company$128
- plus $201 from 7 others
What the payments were for
- Consulting fees$2,43052%
- Travel & lodging$1,00722%
- Food & beverage$1,20826%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Paratek Pharmaceuticals, Inc. | 13 | $3,644 |
| Melinta Therapeutics, LLC | 12 | $184 |
| Insmed, Inc. | 10 | $171 |
| Next Science LLC | 1 | $160 |
| AbbVie | 8 | $157 |
| Viiv Healthcare Company | 5 | $128 |
| Ferring Pharmaceuticals Inc. | 2 | $58 |
| Innovation Technologies Inc | 1 | $37 |
| GSK | 1 | $28 |
| Vertex | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Merck | 1 | $17 |
| Sanofi | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,645 in reported general payments places this provider in the 90th percentile of 56 infectious disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CresembaIsavuconazonium Sulfate | 13 | $69,205 |
| Cefepime Hcl | 38 | $6,270 |
| MicafunginMicafungin Sodium | 13 | $5,699 |
| Rifabutin | 13 | $3,014 |
| Ethambutol Hcl | 36 | $1,907 |
| Azithromycin | 35 | $1,653 |
| Rifampin | 27 | $1,628 |
| Fluconazole | 20 | $1,300 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 11 | $162 |
| Amoxicillin | 13 | $46 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Leawood
- Guillermo CouchonnalLeawood$619
- Daniel GehaLeawood$12
- Thomas MooreWichita$37K
- Wissam El AtrouniKansas City$15K
- Maha AssiWichita$9K
- John FriedOverland Park$7K
- Margaret HaganWichita$4K
- Apoorv KalraOverland Park$3K
- Samir DesaiShawnee$3K
- Dana HawkinsonKansas City$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.